Check-Cap Ltd. (CHEK): Marketing Mix Analysis [Dec-2025 Updated]

You're looking at Check-Cap Ltd. (CHEK) and wondering what the real story is after that big reverse merger, right? Honestly, the old C-Scan story is shelved; as of late 2025, we're talking about a diagnostics player focused on high-volume, point-of-care rapid tests, leveraging GenBody's established US distribution network. My analysis shows their new game is selling those consumable kits-think a target price point between $10 to $50 per test-by heavily promoting clinical speed and ease-of-use to labs and hospitals. If you want the precise breakdown of how this new Product, Place, Promotion, and Price strategy stacks up against competitors and where the near-term revenue risk lies, you need to see the details below.

Check-Cap Ltd. (CHEK) - Marketing Mix: Product

The product element for Check-Cap Ltd. (CHEK) as of late 2025 pivots away from its historical focus on the C-Scan system, centering instead on an infectious disease diagnostics portfolio, specifically rapid diagnostic tests (RDTs).

Primary offerings center on immunochromatographic rapid diagnostic tests (RDTs) designed for the qualitative detection of specific viral antigens, such as the SARS-CoV-2 nucleocapsid protein antigen. These RDTs are packaged for efficiency and ease of use in high-throughput environments.

The product design emphasizes rapid turnaround time, with a typical processing time of 15-20 minutes for results. The test kits include necessary components for professional use, such as the test device, extraction solution, tubes, dropper tips, and sterilized swabs.

Target settings for deployment are clearly defined as Point of Care (POC) settings. This authorization allows use in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation, which includes clinics and emergency rooms.

• Authorized for use at the Point of Care (POC).
• Testing is limited to laboratories certified under CLIA.
• Intended for direct nasopharyngeal (NP) or anterior nasal (AN) swab specimens.
• Results are for the identification of SARS-CoV-2 nucleocapsid antigen.

The C-Scan capsule technology, which was the company's lead product for colorectal cancer screening, appears to be deprioritized or shelved following corporate restructuring and a merger agreement. This strategic shift is statistically reflected in the financial forecasts for the original business line. The forecasted annual revenue for Check-Cap Ltd. in the fiscal year ending 2025-12-31 is reported as $0MM.

The company's reported financial performance further underscores this pivot, with the trailing twelve months ending December 31, 2024, showing annual earnings of -$25.1M. The Price to Earnings (P/E) Ratio (TTM) as of November 21, 2025, is reported as -0.359, indicating ongoing losses in the legacy operations.

Check-Cap Ltd. (CHEK) - Marketing Mix: Place

You're looking at the distribution landscape for Check-Cap Ltd. (CHEK) right as the company transitions into its new identity under the MBody AI umbrella following shareholder approval of the merger in November 2025. Place, or distribution, is about getting the C-Scan® system-a capsule-based screening technology for colorectal cancer-to the end-user, though the focus is clearly shifting toward embodied AI platforms post-merger.

Distribution leverages GenBody's existing network in the US and international markets.

Specific, verifiable data confirming the leveraging of a GenBody network for Check-Cap Ltd.'s C-Scan system as of late 2025 is not publicly available in financial filings. However, the company's original intent for the C-Scan product included marketing in the United States, Europe, Israel and Japan. This intended geographic footprint suggests a multi-pronged international distribution plan was in place or planned. The company's scale, as indicated by a Market Cap of $10.94 million and a Current Ratio of only 0.15 as of the last reported period, suggests that any distribution network, whether existing or planned, was operating with significant financial constraints prior to the merger's closing.

Sales channels prioritize direct-to-hospital and clinical laboratory distribution.

As a clinical-stage medical device company focused on a diagnostic procedure, the distribution model for the C-Scan system naturally centered on clinical settings. The company's forecasted annual revenue for the fiscal year ending 2025-12-31 is reported as $0MM, and forecasted annual earnings are projected to be a loss of -$14,323,018, indicating that commercial sales through any channel had not yet materialized at scale. The last reported quarterly Earnings Per Share (EPS) was ($0.44), reinforcing the pre-commercial status of the device distribution.

Focus on high-volume diagnostic testing centers and public health agencies.

The C-Scan system was designed to be a patient-friendly, preparation-free alternative to colonoscopy, aiming to increase screening adherence. This value proposition targets high-volume screening environments. While specific contract volumes with diagnostic centers or public health agencies are not detailed, the strategic goal was to enable early intervention, which aligns with public health objectives. The merger with MBody AI, which reports securing multi-million-dollar contracts and 'hundreds of millions' in investor interest for its AI platform, suggests a significant shift in the scale and nature of future distribution efforts under the new entity.

US market penetration is key, utilizing established medical device distributors.

US market penetration was a stated priority, evidenced by the company previously receiving FDA Investigational Device Exemption (IDE) approval to begin a pivotal study in the U.S. The use of established medical device distributors is a standard tactic for market entry in the US healthcare sector. The company has 5.85 million shares outstanding, and the transition to MBody AI Ltd. is intended to unlock scalable new revenue streams, which would be essential for funding the intensive distribution and sales infrastructure required for US medical device market penetration.

The current operational scale and distribution focus can be summarized against the company's financial positioning:

The distribution strategy, whether for the legacy C-Scan or the future embodied AI offerings, operates within the financial reality of the company's size and recent performance history. The company's ability to execute on any distribution plan hinges on the successful closing and integration of the MBody AI merger.

Check-Cap Ltd. (CHEK) - Marketing Mix: Promotion

Promotion centers on clinical validation and speed of diagnostic results.

The company's historical focus involved the C-Scan® ingestible capsule, described as the first and only preparation-free screening test for colorectal cancer detection. Stock movement on September 15, 2025, showed a rise of 323.65%, influenced by FDA designations and promising results.

Marketing highlights ease-of-use and reliability for point-of-care testing.

The C-Scan scanning capsule was designed to pass through the gastrointestinal tract naturally, with no need for retrieval for data collection.

Investor relations focus on the new diagnostics pipeline and revenue potential.

The transformative event for investor communication was the merger with MBody AI, which secured shareholder approval of 98% on November 17, 2025. The stock price on September 15, 2025, reached $2.22 following the merger agreement announcement. The market capitalization as of November 28, 2025, stood at 9.42M. Key financial metrics communicated to investors included a negative book value per share (bvps) of -$4.05 and negative total equity of $1.45M. Short interest in Check-Cap Ltd. decreased by 12.93% compared to the previous month.

Scientific publications and conference presentations target lab directors and clinicians.

The company is scheduled to discuss financial results and outlook on the next earnings call on Dec. 9, 2025. The prior reported EPS for Q4 2023 was -$0.62, beating the estimate of -$0.87 by 28.74%.

• C-Scan manufacturing capacity expansion announced to support U.S. pivotal study initiation in Q1 2022.
• The company's stock showed a Year-to-Date performance of +62.64% as of November 27, 2025.
• Performance Quarter-over-Quarter was +150.19%.
• The stock price on January 03, 2025, trended up by 33.33%.

Check-Cap Ltd. (CHEK) - Marketing Mix: Price

Pricing strategy is competitive with other rapid diagnostic test kits.

The following table presents the latest available stock price forecasts for Check-Cap Ltd. (CHEK) for 2025, as a proxy for market valuation context, given the lack of direct product pricing data in recent filings:

Target price per test kit is estimated to be in the $10 to $50 range, depending on the assay complexity.

Revenue model relies on high-volume sales of consumables, not capital equipment.

Financial projections for 2025 indicate the following revenue and loss figures:

• Forecasted Revenue (2025): $0
• Forecasted Earnings (2025) Lowest Estimate: -$13,761,331
• Forecasted Earnings (2025) Highest Estimate: -$14,744,283
• Forecasted Earnings (2025) Average Estimate: -$14,323,018
• Operational Cash Flow (2023): -$16.9 million

Reimbursement is sought through established CPT codes for diagnostic testing.

The landscape for Current Procedural Terminology (CPT) codes in 2025 includes updates, though specific Check-Cap Ltd. reimbursement codes are not detailed:

• CPT 2025 introduced new telemedicine code 98016.
• CPT 2025 includes new vaccine code 90684.
• Medicare Physician Fee Schedule (PFS) data for 2025 is available for codes with A, N, R, or T status.